24 February 2018: 2018 marks an exciting milestone for Sysmex Asia Pacific as we celebrate our 20th anniversary!

“Although it coincides with an even bigger anniversary, Sysmex Corporation celebrating its 50th birthday, we want to pay special attention to our two decades of commitment to the Asia Pacific region,” remarked Frank Buescher, President & CEO of Sysmex APAC.

20 February 2018: Sysmex Celebrates Its 50th Anniversary of Establishment

Sysmex Corporation celebrated the 50th anniversary of its establishment on February 20, 2018. We offer our heartfelt appreciation for the support of our customers and all other stakeholders since the time of our establishment in 1968.

18 January 2018: Liquid Biopsy performance comparison of OncoBEAM RAS CRC and Idylla ctKRAS testing presented at ASCO GI 2018 meeting

Hamburg, Germany, 2018.01.16 – Sysmex Inostics, a global leader in blood based circulating tumor DNA (ctDNA) analysis and molecular diagnostics for oncology, today announces data from an abstract of a study comparing the performance of plasma RAS mutation detection by two commercial liquid biopsy testing platforms, OncoBEAM RAS CRC and Idylla ctKRAS Mutation Test. The […]

06 December 2017: Sysmex Asia Pacific signed distribution agreement with genedrive for HCV

Sysmex Asia Pacific Pte Ltd, a subsidiary of Sysmex Corporation signed a distribution agreement with genedrive plc the near patient molecular diagnostics company, for its CE-marked Genedrive® HCV ID Kit and Genedrive® platform in the Asia Pacific region. This is genedrive’s second agreement signed with a subsidiary of Sysmex Corporation, a world leader in clinical […]

20 September 2017: Sysmex partner with Pantai Premier Pathology and Merck for new liquid biopsy testing to be used in Metastatic cases of colorectal cancer

Colorectal cancer is the second most commonly occurring cancer in Malaysia (Malaysian National Cancer Registry Report 2007-2011).  A new liquid biopsy testing to monitor the progression of metastatic cases of colorectal cancer is now available at Pantai Premier Pathology, Malaysia. The new liquid biopsy testing allows oncologists and surgeons to examine a ‘snapshot’ of the […]

13 September 2017: Sysmex Selected for Inclusion in the Dow Jones Sustainability World Index for the Second Consecutive Year

The Dow Jones Sustainability Indexes are developed through collaboration between S&P Dow Jones Indices of the United States and Robeco SAM, a Swiss research specialist in the area of socially responsible investment. This year Sysmex has been selected for inclusion in the DJSI World for the second consecutive year.

10 August 2017: Sysmex, Hyogo Pharmaceutical Society and Shinkai Transport Systems Enter Agreement to Cooperate on Disaster Relief Activities

Creating a System for Operating Mobile Pharmacies as a Disaster Response Measure – Sysmex Corporation, the Hyogo Pharmaceutical Society and Shinkai Transport Systems, Ltd. announce the signing of an agreement to cooperate on disaster relief activities, aimed at operating mobile pharmacies in times of disaster.

01 June 2017: Sysmex Continuing to Participate in the Global Health Innovative Technology Fund

In order to continue supporting the initiatives of the GHIT Fund, which aims to assist in the application of Japanese technological innovation to healthcare in developing countries, we will be extending our provision of donations for a five-year period from 2018. By participating in the GHIT Fund, we will move forward with initiatives to develop […]

01 June 2017: Sysmex Opens New R&D Facility with a View toward the Realization of Personalized Medicine

Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) has opened a new R&D facility within its Kawasaki INnovation Gateway at SKYFRONT in the city of Kawasaki, Kanagawa Prefecture, to pursue R&D in bioinformatics, a key technology toward the realization of personalized medicine.

31 May 2017: Sysmex Acquires UK Company to Expand into New Business Domains toward Personalized Medicine

Sysmex Corporation has reached an agreement with Oxford Gene Technology IP Limited (“OGT”) to acquire all shares in OGT. Through this move, Sysmex aims to obtain OGT’s business and expertise in the cytogenetics1 domain and its reagent development capabilities used in next-generation sequencers (NGSs)2, thereby reinforcing its base in the life science business.

25 May 2017: Sysmex Receives Invention Award in the 2017 National Commendation for Invention

Sysmex Corporation has received the Invention Award in the National Commendation for Invention1, sponsored by the Japan Institute of Invention and Innovation, for its hematology analyzers that enables the rapid evaluation of the effects of administering iron preparations. The award ceremony is scheduled to be held in Tokyo on Monday, June 12.

21 May 2017: Sysmex New Zealand Commence Direct Sales of Urinalysis Instrument Portfolio

Sysmex New Zealand has been synonymous with the Delphic and Eclair suite of lab and clinical IT solutions for over three decades. The Sysmex New Zealand team are excited to announce, effective 1st May we will be managing the direct sales and support of the Sysmex Urinalysis instrument portfolio.

Please help us to serve you better by sharing your experience.

Do you find the resources provided at this site useful?

What scientific topics you would be most interested to read?